Nuvation Bio(NYSE) NUVB

Market Cap$2.13B

Since IPO (2020)-37%

5 Year-28%

1 Year+160%

1 Month+8%

$6.10

-4.32%

-0.27Today

After hours$6.12+$0.02 (+0.33%)

Nuvation Bio last closing stock price
Metric	Price	Date
Last close	USD 6.11	2026-08-06

Nuvation Bio stock price return by period
Period	Price return	Price at period start	Period start date
1 week	-8.81%	USD 6.70	2026-07-30
1 month	+7.76%	USD 5.67	2026-07-07
3 month	+27.56%	USD 4.79	2026-05-08
Year to date	-31.81%	USD 8.96	2025-12-31
1 year	+160%	USD 2.35	2025-08-06
3 year	+213.33%	USD 1.95	2023-08-07
5 year	-27.61%	USD 8.44	2021-08-06
Since inception	-37.01%	USD 9.70	2020-08-26

Nuvation Bio Financials at a Glance

Market Cap

$2.13B

Revenue (TTM)

$169.90M

Net Income (TTM)

-$149.83M

EPS (TTM)

-$0.43

P/E Ratio

-14.27

Dividend

$0.00

Beta (Volatility)

1.38 (Average)

Dividend

$0.00

Beta (Volatility)

1.38 (Average)

Price

$6.10

Volume

8,394,940

Open

$6.06

Price

$6.10

Volume

8,394,940

Open

$6.06

Previous Close

$6.11

Daily Range

$6.01 - $6.63

52-Week Range

$2.18 - $9.75

Estimated Earnings Date

Nov 2, 2026

Dividend

$0.00

Beta (Volatility)

1.38 (Average)

Price

$6.10

Volume

8,394,940

Open

$6.06

Previous Close

$6.11

Daily Range

$6.01 - $6.63

52-Week Range

$2.18 - $9.75

Estimated Earnings Date

Nov 2, 2026

NUVB News

Nuvation Bio Stock Is Up 190% Despite Recent Pressure. Should Investors Care About This $753,000 Insider Sale?

Jonathan PoncianoJun 29, 2026

Veteran Pharma VC Insider Buys 25,000 Nuvation Bio Shares as New Drug Gains Momentum

Brendan CoffeyJun 17, 2026

Insider Sells 200K Shares of Biotech Company Nuvation Bio

Pamela KockApr 13, 2026

Nuvation Bio Stock Up 130% This Past Year as One Fund Discloses $3 Million Buy

Jonathan PoncianoMar 3, 2026

Nuvation Bio Chief Scientist Sells 100,000 Shares Under Trading Plan — Here's What to Know About the Stock

Jonathan PoncianoNov 3, 2025

Scientists in a lab, monitor, microscope

Why Nuvation Bio Stock Is Skyrocketing Today

Keith SpeightsSep 30, 2025

NUVB Sales Jump 1,043% on Drug Launch

Motley Fool Markets TeamAug 7, 2025

NUVB: Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Nuvation Bio

Nuvation Bio makes medicines for people fighting difficult types of cancer. Its treatments target specific proteins that cause tumors to grow and spread. The company helps patients find new options when standard therapies fail.

Fighting Cancer With Chemistry

IBTROZI: Oral drug for adults with a specific lung cancer called ROS1-positive non-small cell lung cancer.
Safusidenib: Targeted brain tumor treatment designed to pass through the blood-brain barrier to reach cancer cells.
Drug-Drug Conjugates: Technology platform that fuses two cancer-fighting molecules together to target tumors more precisely.
NUV-868: Small molecule that regulates proteins controlling tumor growth and differentiation.

How the Pipeline Is Growing

Acquired AnHeart Therapeutics Ltd. in April 2024 to add new clinical-stage programs to its pipeline.
Partnered with Eisai in January 2026 to develop and sell its lead drug in Europe and other territories.
Collaborated with Innovent to manage the development and commercial use of taletrectinib in China.
Signed an agreement with Nippon Kayaku to commercialize its lead product candidate in Japan.

What Makes the Science Different?

The Drug-Drug Conjugate platform creates treatments that are highly cell permeable and simpler to manufacture than traditional antibody-based drugs. The team uses deep medicinal chemistry experience to improve the safety and activity of oncology targets.

Recent Financial Performance

Revenue hit $41.9 million in Q4 2025, up 633.1% from Q4 2024.
Gross profit reached $41.4 million in Q4 2025, up 2,672% year over year.
Net losses narrowed to $36.6 million in Q4 2025, an improvement of 26% from Q4 2024.
Operating cash flow improved to a $29.7 million deficit in Q4 2025, up 35.8% from the prior year.

The Evolution of Nuvation

Nuvation Bio has evolved from a start-up into a global oncology company with its first approved drug. Its combination of internal research and strategic acquisitions supports its goal of solving tough challenges in cancer treatment.

AI Generated • May 4, 2026

Industry

Pharmaceuticals

Sector

Health Care

Employees

298

CEO

David T. Hung, MD

Website

www.nuvationbio.com

Headquarters

New York City, NY 10036, US

NUVB Financials

Key Financial Metrics (TTM)

Gross Margin

88.90%

Operating Margin

-81.00%

Net Income Margin

-88.19%

Return on Equity

-49.73%

Return on Capital

-67.45%

Return on Assets

-20.12%

Earnings Yield

-7.01%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$2.13B

Shares Outstanding

349.20M

Volume

8.39M

Avg. Volume

6.40M

Financials (TTM)

Gross Profit

$159.60M

Operating Income

-$137.63M

EBITDA

-$127.04M

Operating Cash Flow

-$82.62M

Capital Expenditure

-$101.00K

Free Cash Flow

-$82.72M

Cash & ST Invst.

$660.96M

Total Debt

$252.14M

Nuvation Bio Performance Analysis

Nuvation Bio annual revenue and year-over-year revenue growth by fiscal year
Fiscal year	Period end	Revenue	YoY growth
2022	2022-12-31	USD 0	N/A
2023	2023-12-31	USD 0	N/A
2024	2024-12-31	USD 7,873,000	N/A
2025	2025-12-31	USD 62,902,000	699.0%

Nuvation Bio sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarter	Period end	QoQ growth
Q3	2025-09-30	171.5%
Q4	2025-12-31	219.1%
Q1	2026-03-31	98.8%
Q2	2026-06-30	-61.9%

Nuvation Bio annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal year	Period end	Diluted EPS	YoY growth
2022	2022-12-31	USD -0.48	9.5%
2023	2023-12-31	USD -0.35	-28.0%
2024	2024-12-31	USD -2.11	510.2%
2025	2025-12-31	USD -0.60	-71.6%

Nuvation Bio sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarter	Period end	QoQ growth
Q3	2025-09-30	5.9%
Q4	2025-12-31	31.3%
Q1	2026-03-31	113.0%
Q2	2026-06-30	-1358.7%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name

Q2 2026YOY CHG

Revenue

$31.69M

+555.6%

Gross Profit

$30.78M

+1263.6%

Gross Margin

0.00%

N/A

Market Cap

$2.13B

N/A

Market Cap/Employee

$7.16M

N/A

Employees

298

N/A

Net Income

-$62.84M

-6.5%

EBITDA

-$55.55M

+4.6%

Quarterly Fundamentals

Name

Q2 2026YOY CHG

Total Cash

$660.96M

+8.8%

Total Debt

$252.14M

+336.5%

Accounts Receivable

$31.71M

+375.0%

Inventory

$19.90M

+3505.3%

Long Term Debt

$244.53M

+385.4%

Short Term Debt

$7.61M

+2.9%

Return on Assets

-20.12%

N/A

Return on Invested Capital

-20.92%

N/A

Free Cash Flow

-$5.02M

+89.6%

Operating Cash Flow

-$5.07M

+89.5%

Other Investments to Explore

People Also Watch

SymbolSymbol / CompanyCompanyPricePrice Chg

AUPHAurinia Pharmaceuticals Inc.

AUPHAurinia Pharmaceuticals Inc.$16.13+6.19%

VRDNViridian Therapeutics, Inc.

VRDNViridian Therapeutics, Inc.$22.51+6.83%

ABCLAbCellera Biologics Inc.

ABCLAbCellera Biologics Inc.$6.53+10.30%

VERAVera Therapeutics, Inc.

VERAVera Therapeutics, Inc.$32.02+5.50%

OCULOcular Therapeutix, Inc.

OCULOcular Therapeutix, Inc.$8.74+2.82%

CLDXCelldex Therapeutics, Inc.

CLDXCelldex Therapeutics, Inc.$41.56+1.22%

GPCRStructure Therapeutics Inc.

GPCRStructure Therapeutics Inc.$52.62+4.14%

Trending Stocks

SymbolSymbol / CompanyCompanyPricePrice Chg

SPCXSpace Exploration Technologies

SPCXSpace Exploration Technologies$114.92+0.06%

NVDANvidia

NVDANvidia$218.99-0.00%

TTDThe Trade Desk

TTDThe Trade Desk$17.67-0.07%

SOUNSoundHound AI

SOUNSoundHound AI$7.08+0.10%

TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares

TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares$7.68-0.01%

INTCIntel

INTCIntel$99.81-0.01%

PATHUiPath

PATHUiPath$14.00+0.01%

Questions About NUVB

What is the current price of Nuvation Bio?

Nuvation Bio is trading at $6.11 per share.

What is the 52-week range for Nuvation Bio?

Over the past 52 weeks, Nuvation Bio has traded between $2.18 and $9.75.

How much debt does Nuvation Bio have?

As of the most recent reporting period, Nuvation Bio reported total debt of $216.98M.

How much cash does Nuvation Bio have on hand?

Nuvation Bio reported $125.39M in cash and cash equivalents in its most recent financial results.

What is Nuvation Bio’s dividend yield?

Nuvation Bio does not currently have a dividend yield.

Nuvation Bio(NYSE) NUVB

Nuvation Bio Financials at a Glance

NUVB News

Nuvation Bio Stock Is Up 190% Despite Recent Pressure. Should Investors Care About This $753,000 Insider Sale?

Veteran Pharma VC Insider Buys 25,000 Nuvation Bio Shares as New Drug Gains Momentum

Insider Sells 200K Shares of Biotech Company Nuvation Bio

Nuvation Bio Stock Up 130% This Past Year as One Fund Discloses $3 Million Buy

Nuvation Bio Chief Scientist Sells 100,000 Shares Under Trading Plan — Here's What to Know About the Stock

Why Nuvation Bio Stock Is Skyrocketing Today

NUVB Sales Jump 1,043% on Drug Launch

NUVB: Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

About Nuvation Bio

Fighting Cancer With Chemistry

How the Pipeline Is Growing

What Makes the Science Different?

Recent Financial Performance

The Evolution of Nuvation

NUVB Financials

Key Financial Metrics (TTM)

Stock Overview

Financials (TTM)

Nuvation Bio Performance Analysis

Revenue Growth Rate

Earnings Per Share Growth Rate

Quarterly Performance

Quarterly Fundamentals

Other Investments to Explore

People Also Watch

Trending Stocks

Questions About NUVB

What is the current price of Nuvation Bio?

What is the 52-week range for Nuvation Bio?

How much debt does Nuvation Bio have?

How much cash does Nuvation Bio have on hand?

What is Nuvation Bio’s dividend yield?

Premium Investing Services